medicina61巻9号

2024年08月発行

特集 リウマチ膠原病疾患Up To Date！—押さえておきたい最新の診断と治療

膠原病関連症状に対する治療

グルココルチコイド誘発性骨粗鬆症

著者： 小澤廣記¹

所属機関： ¹聖路加国際病院Immuno-Rheumatology Center

ページ範囲：P.1537 - P.1545

文献概要

Point
◎ステロイドを長期処方する患者では，必ず骨粗鬆症対策を行う．
◎ビタミンDとカルシウムの摂取を指導・処方する．
◎圧迫骨折のスクリーニングと骨密度検査による骨折リスク評価を行う．
◎骨折リスク・背景疾患に応じて骨粗鬆症薬を選択する．
◎骨密度検査をフォローしながら，逐次療法を考慮する．

参考文献

1）日本骨代謝学会 グルココルチコイド誘発性骨粗鬆症の管理と治療のガイドライン作成委員会（編）：グルココルチコイド誘発性骨粗鬆症の管理と治療のガイドライン2023，南山堂，2023

2）Humphrey MB, et al：2022 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res（Hoboken）75：2405-2419, 2023 PMID 37884467　https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.25240（2024年5月閲覧）

3）Rossini M, et al：Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases；The Glucocorticoid Induced OsTeoporosis TOol（GIOTTO）study. Reumatismo 69：30-39, 2017 PMID 28535619

4）Canalis E, et al：Glucocorticoid-induced osteoporosis；Pathophysiology and therapy. Osteoporos Int 18：1319-1328, 2007 PMID 17566815

5）Angeli A, et al：High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy；A cross-sectional outpatient study. Bone 39：253-259, 2006 PMID 16574519

6）Kanis JA, et al：Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22：809-816, 2011 PMID 21229233

7）骨粗鬆症の予防と治療ガイドライン作成委員会（日本骨粗鬆症学会，日本骨代謝学会，骨粗鬆症財団）（編）：骨粗鬆症の予防と治療ガイドライン2015年版，ライフサイエンス出版，2015

8）de Abajo FJ, et al：Risk of ischemic stroke associated with calcium supplements with or without vitamin D；A nested case-control study. J Am Heart Assoc 6：e005795, 2017 PMID 28522672

9）Liu Z, et al：Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid；A network meta-analysis of randomized controlled trials. PLoS One 15：e0243851, 2020 PMID 33326444

10）Matsumoto T, et al：Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients（e-GLORIA）. J Bone Miner Metab 38：522-532, 2020 PMID 32140784

11）Allen CS, et al：Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev 10：CD001347, 2016 PMID 27706804

12）Saag KG, et al：Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339：292-299, 1998 PMID 9682041

13）Stoch SA, at al：Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss；A 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36：1705-1714, 2009 PMID 19487264

14）Cohen S, et al：Risedronate therapy prevents corticosteroid-induced bone loss；A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42：2309-2318, 1999 PMID 10555025

15）Reid DM, et al：Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women；A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15：1006-1013, 2000 PMID 10841169

16）Eastell R, et al：Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11：331-337, 2000 PMID 10928223

17）Reid DM, et al：Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis（HORIZON）；A multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373：1253-1263, 2009 PMID 19362675

18）Ringe JD, et al：Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology（Oxford）42：743-749, 2003 PMID 12730532

19）Saag KG, et al：Denosumab versus risedronate in glucocorticoid-induced osteoporosis；A multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6：445-454, 2018 PMID 29631782

20）Saag KG, et al：Denosumab versus risedronate in glucocorticoid-induced osteoporosis；Final results of a twenty-four-month randomized, double-blind, double-dummy trial. Arthritis Rheumatol 71：1174-1184, 2019 PMID 30816640

21）Mok CC, et al：Denosumab versus alendronate in long-term glucocorticoid users；A 12-month randomized controlled trial. Bone 146：115902, 2021 PMID 33631355

22）Deng J, et al：Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies；A systematic review and network meta-analysis. Rheumatology（Oxford）60：649-657, 2021 PMID 32572480

23）Lamy O, et al：Severe rebound-associated vertebral fractures after denosumab discontinuation；9 clinical cases report. J Clin Endocrinol Metab 102：354-358, 2017 PMID 27732330

24）Symonds C, Kline G：Warning of an increased risk of vertebral fracture after stopping denosumab. CMAJ 190：E485-E486, 2018 PMID 29685907

25）Saag KG, et al：Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357：2028-2039, 2007 PMID 18003959

26）Saag KG, et al：Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis；Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60：3346-3355, 2009 PMID 19877063

27）Tanaka I, et al：Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis；The TOWER-GO study. J Bone Miner Metab 39：446-455, 2021 PMID 33211212

28）Tanaka I, et al：Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis；A post hoc analysis of the TOWER-GO study. Mod Rheumatol 32：634-640, 2022 PMID 34910192

29）Mok CC, et al：Raloxifene for prevention of glucocorticoid-induced bone loss；A 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis 70：778-784, 2011 PMID 21187295

30）Adomaityte J, et al：Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost 99：338-342, 2008 PMID 18278183

31）Barrett-Connor E, et al：Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355：125-137, 2006 PMID 16837676

32）Saag KG, et al：Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377：1417-1427, 2017 PMID 28892457

33）Langdahl BL, et al：Romosozumab（sclerostin monoclonal antibody）versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy；A randomised, open-label, phase 3 trial. Lancet 390：1585-1594, 2017 PMID 28755782

34）顎骨壊死検討委員会（日本口腔外科学会，他）：薬剤関連顎骨壊死の病態と管理；顎骨壊死検討委員会ポジションペーパー2023, 2023　https://www.jsoms.or.jp/medical/pdf/work/guideline_202307.pdf（2024年5月閲覧）

35）McGowan K, et al：Risk factors for medication-related osteonecrosis of the jaws；A systematic review. Oral Dis 24：527-536, 2018 PMID 28656643

36）AlRowis R, et al：Medication-related osteonecrosis of the jaw（MRONJ）；A review of pathophysiology, risk factors, preventive measures and treatment strategies. Saudi Dent J 34：202-210, 2022 PMID 35935720

37）Hallmer F, et al：Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol 126：477-485, 2018 PMID 30249535

38）Ishimaru M, et al：Prevalence, incidence rate, and risk factors of medication-related osteonecrosis of the jaw in patients with osteoporosis and cancer；A nationwide population-based study in Japan. J Oral Maxillofac Surg 80：714-727, 2022 PMID 35033505

39）Dennis M Black DM, et al：Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 383：743-753, 2020 PMID 32813950